
Lords Mark Industries Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
Yes
Order
Yes
Capex
Yes
4 of 5 growth signals are positive — a strong management growth story.
Full analysisRevenue guidance
Category 2- FY27 revenue projected at around ₹1,550 crores with ~20.8% EBITDA margin and ~12.8% PAT margin.
- FY28 expected consolidated revenue to cross ₹2,100 crores, representing over 25% growth from FY27.
- EBITDA margin for FY28 expected to expand to around 23-24%.
- Dialysis machine production capacity to increase from ~60 machines/month currently to 150 machines/month by end of next year.
- Commercial adoption of dialysis machines growing with confirmed order book of 500+ machines.
- Sickle cell testing expected to contribute significantly to FY28 revenues post-approval and tender.
- New medtech products at commercialization stage anticipated to add revenue from Q4 FY27 onwards.
- Expansion of dialysis centers and 27 cancer centers over 5-7 years to support recurring revenues.
- Strong growth in MedTech expected to outpace renewable energy business revenue, with MedTech contributing over 50% revenue share in coming years.
See what Lords Mark Industries management said on margin guidance — free account, 30 seconds.
Fundraise plans
YesSee what Lords Mark Industries management said on order book — free account, 30 seconds.
Capex plans
Yes- The company plans a capex of around ₹300-350 crores over the next 2-3 years.
- Investment includes setting up a new manufacturing plant for dialysis machines and other upcoming MedTech products.
- A 2-acre site in Lucknow has been acquired to establish India’s/Asia’s largest IVD and biochemistry analyzer manufacturing facility.
- The dialysis manufacturing is currently partly outsourced; the new plant aims to bring production in-house to reduce dependency on OEMs.
- R&D investments target oncology, TB detection, dialysis, genomics, sickle cell screening, and AI integration across devices.
- Strategic focus on partnerships, global expansion (subsidiaries in the UK, Switzerland), and pipeline approvals.
- Plans to expand dialysis centers (50 centers planned) with partners contributing infrastructure investments.
- A strategic option under consideration includes separating renewable business to focus independently on MedTech growth.
Track Lords Mark Industries — get its next earnings analysis in your feed
How does Lords Mark Industries rank vs peers in Commercial Services & Supplies?
Pro featureHow does Lords Mark Industries rank in Commercial Services & Supplies?
Compare Lords Mark Industries against every Commercial Services & Supplies company (Q1 FY27) on revenue, margins and earnings-call signals.
Continue your research
What Lords Mark Industries's management said in earlier quarters
Others in Commercial Services & Supplies this season
- Cadsys (India) (Q2 FY27)
Consolidated revenue for H1 FY 2026-27 was ₹39.85 crore, compared to ₹69.98 crore in H1 FY 2025-26, indicating a year-on-year decline in revenue. Key investor p
- IIRM Holdings (Q2 FY27)
Revenue from Operations for Q2 FY27: ₹672.5 million (Page 15) . Key investor presentation takeaways from IIRM Holdings India Ltd's Q2 FY27 investor presentation
- Manglam Infra (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026 is ₹1,019.03 lakhs, compared to ₹1,300.69 lakhs for the half year ended September 30, 2025…
- Armour Security (Q2 FY27)
210.96 Lakhs (~10.7%) (Page 6). Key results statement takeaways from Armour Security (India) Ltd's Q2 FY27 results statement — and how it ranks against sector p